NUI
No nā nīnau e pili ana i kā mākou huahana a i ʻole ka papa inoa kumukūʻai, e ʻoluʻolu e waiho i kāu leka uila iā mākou a e hoʻopili mākou i loko o 24 mau hola.
NINAU ANOʻO ke kūlana kaʻaahi a me ke ʻano hoʻouna i ʻōlelo ʻia:
ma ka lewa, ma ke kai a ma ke ala pololei
Kūlana mālama:
E mālama ma kahi pouli, Hoʻopaʻa ʻia i kahi maloʻo, Ka Mahana lumi
Ka nui o ke kauoha liʻiliʻi:
Kūkākūkā
palapala hōʻoia:
COA, HPLC, GC, HNMR, Assay, Water Content(KF), TLC loaʻa
Boc-O-Benzyl-L-threonine;
BOC-THR-OH;
BOC-THR(BZL)-OH;
Butoxacarbonylbenzylthreonine;
NT-boc-O-benzyl-L-threonine*crystalline;
O-benzyl-N-tert-butoxycarbonyl-L-threonine;
N-ALPHA-T-BUTYLOXYCARBONYL-O-BENZYL-L-THREONINE;
NALPHA-tert-Butoxycarbonyl-O-benzyl-L-threonine
Hoʻohana mau ʻia lākou no ka ʻeke pauda.A hiki iā lākou ke pale i ka lā a me ka wai mai ka pōʻino.
Hiki i ka pahu paʻakikī ke pale i kāu huahana mai ka hāʻule a pulu.
ʻO ka pauka kristal keʻokeʻo;ʻAʻole hiki ke hoʻoheheʻe ʻia i ka wai a me ka petroleum ether, hiki ke hoʻoheheʻe ʻia i ka ethyl acetate a me ka methanol;mp he 115-116 ℃;Ka hoʻololi kikoʻī [α]20D+15.8°(0.5-2.0 mg/ml, methanol).
Hoʻohana ʻia no ka synthesis polypeptide, ma ke ʻano he monomer pale amino acid.
Ua hoʻokuʻu ʻia ʻo O-benzyl-l-threonine i loko o ka dioxane solution a ua hoʻopaʻa ʻia me ka tert-butylcarbonyl azide e loaʻa ai kahi huahana maʻemaʻe, i unuhi ʻia e ka ethyl acetate ma ka pH o 9-10 a laila recrystallized.
He ʻāpana ikaika o ka thymic oietin Ⅱ o nā mea huna thymus.ʻO Thymoietin II kahi pūhui polypeptide hoʻokahi i hoʻokaʻawale ʻia mai ka hormone thymus.He 49 mau ʻakika amino, a ʻo ka ʻāpana kaulahao peptide i haku ʻia me 5 mau amino acids ua like nā hana physiological like me thymoietin II.No laila, kapa ʻia kēia ʻāpana pentapeptide ʻo thymus pentapeptide.ʻO ke keʻokeʻo maloʻo maloʻo keʻokeʻo a i ʻole ka pauka.
ʻO kekahi o nā kuleana o ka thymus pentapeptide ʻo ia ka hoʻoulu ʻana i ka ʻokoʻa o ka cell T.Hiki iā ia ke hoʻoulu i ka hoʻololi ʻana o nā pūnaewele prothorax Thy-1- i loko o nā pūnaewele T Thy-1+.Hoʻopili ʻia ka ʻokoʻa o ka cell T e ka piʻi ʻana o nā pae cAMP intracellular.ʻO kekahi hana maʻamau o ka thymus pentapeptides, ʻo ia ka hoʻopaʻa ʻana i nā mea hoʻokipa kūikawā o nā keʻena T koko peripheral oo, hoʻonui i ka pae cAMP intracellular, a pēlā e hoʻoulu ai i kahi ʻano o nā hopena intracellular, ʻo ia hoʻi ke kumu o kāna hana immunomodulatory.Ma ke kūlana kino maʻamau, ua hōʻike ka thymus pentapeptide i ka hopena hoʻoikaika kino, hiki ke hoʻonui nui i ka nui o ka hoʻokumu ʻana o ka rosette E a me ka helu hoʻololi ʻana o nā lymphocytes splenic, hoʻonui i nā pae like ʻole o ka pane kūlohelohe mua a lua paha, a hoʻonui i ka helu o ka ʻano IgM a me IgG a i ʻole. ʻO ka ʻano IgA ʻano antibody e hana ana i nā pūnaewele.Hiki nō hoʻi iā Thymus pentapeptide ke hoʻonui i ka hana phagocytosis o macrophages, hoʻonui i ka hana enzyme a me ka phagocytosis o polymorphonuclear neutrophils, hoʻonui i ka ʻike o ka antibody, a hoʻonui i ka hana immune o nā keʻena koko ʻulaʻula.Hiki i ka Thymus pentapeptide ke ho'āla i nā pūnaewele maikaʻi CD4 a me CD8, i hiki ai i nā pūnaewele Tc kiko'ī ke mālama i ke ola lōʻihi, akā hiki ke hoʻoikaika i nā pūnaewele Th a hoʻoulu i ka hana o nā pūnaewele Ts.ʻO nā hopena antiinfectious a me ka therapeutic o thymus pentapeptide e pili ana i kona hoʻonui ʻana i ka hana cell TC.Hiki i ka nui kūpono o ka thymus pentapeptide ke hoʻonui nui i ka hana ʻana o ka interferon i ka pale anti-infection.Hoʻoulu a hoʻoikaika i ka ʻokoʻa a me ka hoʻomaʻamaʻa ʻana o ke kelepona T;ʻO ka CD4/CD8 ka mea maʻamau ma o ka hoʻoponopono ʻana i ka māhele o T lymphocyte subsets;Hoʻonui i ka hana phagocytosis o nā macrophages;Hoʻonui i ka hana palekana o ke koko ʻulaʻula;E hoʻonui i ka hana o nā pūnaewele pepehi kanaka maoli;E hoʻonui i ke kiʻekiʻe o ka hana interleukin-2 a me ka ʻōlelo hoʻokipa;Hoʻonui i ka hana o ka γ interferon i loko o nā ʻāpana mononuclear koko peripheral;Hoʻonui i ka hana SOD i ka serum.
Hiki ke hoʻohana ʻia i nā poʻe maʻi maʻi maʻi maʻi me ka hōʻino ʻana o ka hana ma hope o ka radiotherapy a me ka chemotherapy.Ka mālama ʻana i ka maʻi hepa B;Nā hana ʻokiʻoki nui a me nā maʻi maʻi nui;ʻO nā maʻi autoimmune e like me ka rheumatoid arthritis, lupus erythematosus;ʻO ka maʻi diabetes type II, menopause syndrome;He kanaka me ka nawaliwali o ke kino.
Fmoc-L-Thr(tBu)-Phe-OH | Boc-D-Thr-OH |
HL-Thr-OH | Boc-D-Thr(me)-OH |
DL-Thr | Boc-D-Thr(Bzl)-OH |
HL-allo-Thr-OH | Cbz-Thr-OH |
L-Thr(bzl) | Cbz-Thr-Obzl |
HL-Thr(tBu)-OH | ZL-Thr-ome |
L-Thr(me) | Cbz-D-Thr-OH |
Thr-Otbu.hcl | Cbz-L-Thr(tBu)-OH |
L-Thr(bzl).HCl | Cbz-L-Thr(bzl)-OH |
L-Thr(me).Hcl | Cbz-L-Thr(tBu)-OH DCHA |
L-Thr-Obzl.HCl | Fmoc-L-Thr-OH |
HL-Thr-OMe.HCl | fmoc-L-Thr-OtBu |
L-Thr-Oet.Hcl | Fmoc-L-Thr-Obzl |
L-Allo-Thr-Ome.Hcl | Fmoc-L-Allo-Thr-OH |
HL-Thr-OBzl·oxalate | Fmoc-Thr(tBu)-OH |
D-Thr(bzl).HCl | Fmoc-L-Thr(bzl)-OH |
D-Thr-Oet.Hcl | Fmoc-D-Thr-OH |
D-Thr-Obzl.HCl | Fmoc-D-Thr(bzl)-OH |
D-Thr-Ome.HCl | Fmoc-D-Thr(tBu)-OH |
DL-Thr-Ome.HCl | Fmoc-L-Thr(tBu)-Ser-OH |
Boc-L-Thr-OtBu | Boc-n-me-l-thr(bzl).CHA |
Boc-L-Thr-OH | Fmoc-N-Me-L-Thr(bzl)-OH |
Boc-L-allo-Thr-OH | Fmoc-L-Thr(tBu)-Gly-OH |
Boc-Thr-OMe | (2S,3S)-2-Amino-3-methoxybutanoic acid/L-AlloThr(Me) |
Boc-Thr-Obzl | (2S,3S)-2-Amino-3-methoxybutanoic acid/BOC-AlloThr(Me) |
Boc-L-Thr(tBu)-OH | HL-Thr(Bzl)-OBzl.oxalate |
Boc-L-Thr(Bzl)-OH | Boc-D-Thr-Ome |
Boc-L-Thr(me)-OH |
1. Loaʻa ka lawelawe R&D
2. ʻO ka mea hana i hōʻoia ʻia ʻo ISO, hōʻoia maikaʻi
3.A piha piha o ka lawelawe ukali i ka wā hana
4.High kumu kūʻai pono
Nā palapala hōʻoia 5.Quality i hāʻawiʻia no ka noi a ka mea kūʻai
6.Great ma hope o ke kūʻai aku, mālama i ka pilina pili me ka mea kūʻai
7.Full punawai e kōkua i ka ho'ēmiʻana i ke kumukūʻai moku
8.Free hāpana hāʻawi ʻia e nānā i ka maikaʻi ma mua o kekahi uku
9.Payment manawa kūkākūkā
10.Assit nā mea kūʻai aku e pili ana i nā hihia ma Kina